Mersana Therapeutics在1月5日更新了XMT-1536(UpRi)的临床数据。XMT-1536是靶向NaPi2b的抗体偶联药物(ADC),在1期临床的卵巢癌拓展队列中,ORR数据从去年5月公布的35%下降至28%,安全性上有31%的患者由于治疗引起的不良反应减少剂量、推迟用药或停止治疗,39%的患者发生严重不良事件,发生了1例5级肺炎。截止1月5日...
2022-RA-459-ESGOUPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancerdoi:10.1136/ijgc-2022-ESGO.511Introduction/Background UpRi is a first-in-class NaPi2b-...
其他即將推出的數據演示:2024年上半年,Mersana預計將在多個科學會議上展示數據,證明Dolasynthen與第一代細胞毒性ADC平台的區別。演講將包括兩種已停產的ADC候選藥物XMT-1592和XMT-1536(UpRi)的臨床數據。合作:Mersana繼續推進與JanssenBiotech, Inc.和德國達姆施塔特默克公司的合作。與Janssen的合作和許可協議的重點是為多...
· 英文名称 Upifitamab Rilsodotin(UpRi)/XMT-1536 · 结构 · 简介 Upifitamab Rilsodotin(XMT-1536)是一种新型抗体-药物偶联物(ADC),由靶向NaPi2b的IgG抗体与细胞毒性药物AF-HPA通过创新型连接子偶联而成。XMT-1536能够实现肿瘤表面药物浓度的显著提升,同时其有效载荷AF-HPA具备可控的旁观者效应和有限的扩...
Mersana has previously developed and are in the process of testing other ADC’s such as, upifitamab rilsodotin (UpRi), a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT (NCT03319628),3 a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as...
TP036/#426Uplift (ENGOT-OV67/GOG-3048) a pivotal cohort of the XMT-1536–1 trial of upifitamab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancerdoi:10.1136/ijgc-2022-igcs.545...
UpRi activity was observed in pts previously failing platinum, bevacizumab, and PARP inhibitors. These data support further clinical development of UpRi in a single-arm registrational strategy utilizing 36mg/m2up to a max dose of approximately 80mg every four weeks (UPLIFT; NCT03319628)....
Upifitamab rilsodotin (UpRi) is a Dolaflexin, high Drug-to-Antibody Ratio ADC targeting NaPi2b, a sodium-dependent phosphate transporter broadly expressed in high-grade serous epithelial ovarian cancer, with limited expression in normal tissues. UPLIFT was a single-arm Ph2 trial evaluating the ...
EP017/#425Comparison of NAPI2B expression from paired tissue samples in a clinical study of upifitamab rilsodotin (UPRI; XMT-1536) supports a strategy of testing in archive materialdoi:10.1136/ijgc-2022-igcs.108Objectives UpRi is a first-in-class NaPi2b ADC with a novel scaffold-linker...